Insilico Medicine Apr 20, 2026 Insilico Medicine Advances AI-Driven Target Discovery with Validated TargetPro–TargetBench Framework - Insilico Medicine
Insilico Medicine Apr 20, 2026 Insilico Medicine Showcases AI Drug Discovery Platform at AACR 2026 - TipRanks
Insilico Medicine Mar 29, 2026 Insilico Medicine Announces 2025 Annual Results, Redefining Value Delivery in AI-Powered Drug Discovery - Insilico Medicine
Endpoints News Jan 27, 2026 Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
FierceBiotech Jan 27, 2026 Qilu programs path into cardiometabolic disease with $120M, AI-enabled Insilico alliance
Endpoints News Jan 21, 2026 Fosun-funded Hygtia Therapeutics licenses Insilico’s NLRP3 inhibitor for Parkinson’s